4-pyridinonetriazine derivatives as HIV integrase inhibitors

US9714243B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Mark W. Embrey · North Wales, US
• Thomas H. Graham · Somerville, US
• Abbas M. Walji · Lansdale, US
• Sherman T. Waddell · Westfield, US
• Tao Yu · Shanghai, CN
• Yonglian Zhang · Metuchen, US
• Wensheng Liu · Edison, US
• Paul J. Coleman · Wallingford, US
• John S. Wai · Harleysville, US
• Thomas Steele · Schwenksville, US
• Christina Ng Di Marco · Conshohocken, US

Key dates

• Filing date: Dec 12, 2013
• Grant date: Jul 25, 2017
• Expiry date: Dec 12, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6521
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 4-Pyridinonetriazine Derivatives of Formula (I); and pharmaceutically acceptable salts thereof, wherein A, X, Y, R1, R2, R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridinonetriazine Derivative, and methods of using the 4-Pyridinonetriazine Derivatives for treating or preventing HIV infection in a subject.